

Avelumab JAVELIN Merkel 200 (Part B - treatment-naïve patients)

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



Not qualified for an ESMO-MCBS credit



#### Serious and disabling adverse effects



#### Other adjustments



Upgraded based on expanded access and real-world experience



Avelumab JAVELIN Merkel 200 (Part B - treatment-naïve patients)

### SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Skin Cancers

Therapeutic Indication: Adult patients with metastatic Merkel cell carcinoma (MCC)

Experimental Arm: Avelumab

Control Arm: Single arm (Phase II)



